Lawrence A. Leiter

MDCM, FRCPC, FACP, FACE, FAHA

Associate Scientist, Li Ka Shing Knowledge Institute

Biography

Please note: Dr. Leiter is not taking any summer students in 2019.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 500 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas.

Dr. Leiter is the past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and is a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. He also received the 2005 CSEM Educator of the Year Award, and the 2006 CDA Gerald S. Wong Award in recognition of significant contributions to the diabetes community. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.

 

Recent Publications

  1. Goldberg, AC, Leiter, LA, Stroes, ESG, Baum, SJ, Hanselman, JC, Bloedon, LT et al.. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322 (18):1780-1788. doi: 10.1001/jama.2019.16585. PubMed PMID:31714986 .
  2. Mazer, CD, Hare, GMT, Connelly, PW, Gilbert, RE, Shehata, N, Quan, A et al.. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease. Circulation. 2019; :. doi: 10.1161/CIRCULATIONAHA.119.044235. PubMed PMID:31707794 .
  3. Ray, KK, Del Prato, S, Müller-Wieland, D, Cariou, B, Colhoun, HM, Tinahones, FJ et al.. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovasc Diabetol. 2019;18 (1):149. doi: 10.1186/s12933-019-0951-9. PubMed PMID:31706300 PubMed Central PMC6842201.
  4. Eckel, RH, Farooki, A, Henry, RR, Koch, GG, Leiter, LA. Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. Clin Diabetes. 2019;37 (4):316-337. doi: 10.2337/cd19-0001. PubMed PMID:31660005 PubMed Central PMC6794224.
  5. Wright, RS, Collins, MG, Stoekenbroek, RM, Robson, R, Wijngaard, PLJ, Landmesser, U et al.. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin. Proc. 2019; :. doi: 10.1016/j.mayocp.2019.08.021. PubMed PMID:31630870 .
  6. Ray, KK, Stoekenbroek, RM, Kallend, D, Nishikido, T, Leiter, LA, Landmesser, U et al.. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. JAMA Cardiol. 2019; :. doi: 10.1001/jamacardio.2019.3502. PubMed PMID:31553410 PubMed Central PMC6763983.
  7. Tinahones, FJ, Laufs, U, Cariou, B, Louie, MJ, Yang, J, Thompson, D et al.. Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials. Diabetes Metab. 2019; :101120. doi: 10.1016/j.diabet.2019.101120. PubMed PMID:31533069 .
  8. Bhatt, DL, Steg, PG, Mehta, SR, Leiter, LA, Simon, T, Fox, K et al.. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394 (10204):1169-1180. doi: 10.1016/S0140-6736(19)31887-2. PubMed PMID:31484629 .
  9. Hess, DA, Terenzi, DC, Trac, JZ, Quan, A, Mason, T, Al-Omran, M et al.. SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metab. 2019;30 (4):609-613. doi: 10.1016/j.cmet.2019.08.015. PubMed PMID:31477497 .
  10. Steg, PG, Bhatt, DL, Simon, T, Fox, K, Mehta, SR, Harrington, RA et al.. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N. Engl. J. Med. 2019;381 (14):1309-1320. doi: 10.1056/NEJMoa1908077. PubMed PMID:31475798 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto
X